Emergency Unblinding Section
An Emergency Unblinding section documents who may break the blind, under what circumstances, by what mechanism, and how the event is recorded while preserving the blind for everyone else when possible.
An Emergency Unblinding section explains the criteria, authority, mechanism, documentation, and follow-up for breaking a treatment blind when participant care requires it.
Key details
Important caveats
Scope Boundary
This is distinct from the general Blinding section, which describes how masking is created and maintained. Exact procedures depend on the intervention, trial design, sponsor system, and applicable requirements.
Further guidance
Content
State emergency criteria, authorized roles, access mechanism, availability, documentation/notification steps, and measures that limit disclosure to the affected participant or necessary personnel.
Purpose
Protect participant care without allowing avoidable disclosure of treatment assignments to compromise trial integrity.
Sources and evidence
Sources are shown with the role they play in this guide. Historical or style-sensitive claims are kept within the evidence boundary described above.
- E6(R3) Good Clinical Practice Guidance for Industry — September 2025 (opens in a new tab)U.S. Food and Drug Administration · Current ICH E6(R3) GCP guidance on investigator oversight, training/delegation, participant withdrawal, investigational-product accountability, site close-out, essential records, and insurance/indemnification
- E6(R3) Good Clinical Practice (GCP) — September 2025 (opens in a new tab)U.S. Food and Drug Administration · Current FDA final-guidance overview for ICH E6(R3), including quality by design, risk-based quality management, technology, proportionality, and clarified sponsor/investigator responsibilities